tiprankstipranks
SciBase Holding AB (DE:5J3)
:5J3
Germany Market

5J3 Stock Chart & Stats


---

SciBase Holding AB News

---

Financials

Annual

5J3 FAQ

What was SciBase Holding AB’s price range in the past 12 months?
SciBase Holding AB lowest stock price was €0.00 and its highest was €0.05 in the past 12 months.
    What is SciBase Holding AB’s market cap?
    SciBase Holding AB’s market cap is €7.46M.
      When is SciBase Holding AB’s upcoming earnings report date?
      SciBase Holding AB’s upcoming earnings report date is Feb 25, 2025 which is in 26 days.
        How were SciBase Holding AB’s earnings last quarter?
        SciBase Holding AB released its earnings results on Nov 12, 2024. The company reported -€0.007 earnings per share for the quarter, beating the consensus estimate of -€0.007 by <€0.001.
          Is SciBase Holding AB overvalued?
          According to Wall Street analysts SciBase Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does SciBase Holding AB pay dividends?
            SciBase Holding AB does not currently pay dividends.
            What is SciBase Holding AB’s EPS estimate?
            SciBase Holding AB’s EPS estimate is >-0.01.
              How many shares outstanding does SciBase Holding AB have?
              SciBase Holding AB has 219,538,400 shares outstanding.
                What happened to SciBase Holding AB’s price movement after its last earnings report?
                SciBase Holding AB reported an EPS of -€0.007 in its last earnings report, beating expectations of -€0.007. Following the earnings report the stock price went same 0%.
                  Which hedge fund is a major shareholder of SciBase Holding AB?
                  Currently, no hedge funds are holding shares in DE:5J3
                  ---

                  Company Description

                  SciBase Holding AB

                  SciBase Holding AB is a medical technology company that develops devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. The company operates in two segments: skin cancer and skin barrier assessment. Its geographical segments are Europe/Rest of the World, US/North America, and Asia/Oceania. It derives most of its revenue from the Europe/Rest of the World segment.
                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Metro AG
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis